Atea Pharmaceuticals (AVIR) EBITDA: 2019-2024
Historic EBITDA for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$168.4 million.
- Atea Pharmaceuticals' EBITDA fell 129.25% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$116.6 million, marking a year-over-year decrease of 190.89%. This contributed to the annual value of -$168.4 million for FY2024, which is 24.65% down from last year.
- According to the latest figures from FY2024, Atea Pharmaceuticals' EBITDA is -$168.4 million, which was down 24.65% from -$135.1 million recorded in FY2023.
- In the past 5 years, Atea Pharmaceuticals' EBITDA registered a high of $121.2 million during FY2021, and its lowest value of -$168.4 million during FY2024.
- Moreover, its 3-year median value for EBITDA was -$135.1 million (2023), whereas its average is -$140.0 million.
- In the last 5 years, Atea Pharmaceuticals' EBITDA surged by 1,207.06% in 2021 and then tumbled by 196.21% in 2022.
- Atea Pharmaceuticals' EBITDA (Yearly) stood at -$10.9 million in 2020, then surged by 1,207.06% to $121.2 million in 2021, then tumbled by 196.21% to -$116.6 million in 2022, then declined by 15.84% to -$135.1 million in 2023, then declined by 24.65% to -$168.4 million in 2024.